Healthcare and Life Science
How movement and physiotherapy can reduce stress at work
Modern workplaces often involve long hours sitting at desks, tight deadlines, and constant digital communication. These factors can significantly increase stress levels and negatively affect both physical and mental health. Incorporating regular movement and physiotherapy principles int...
Lab Thread introduces Unified Lab Software Platform to streamline biological research
Connects scientific teams, data and workflows within a single, fully integrated digital lab management system ...
EpilepsyGTx appoints Professor Dimitri Kullmann as Chief Scientific Officer
Appointment of UCL Neurologist will accelerate the delivery of novel gene therapies for refractory epilepsy ...
Isogenica Ltd. and Axxam S.p.A. Announce Collaboration to Provide Unique VHH Antibody Discovery Solutions
Axxam S.p.A. and Isogenica Ltd. have announced a partnership to bring together functional bioassay capabilities with unique antibody discovery solutions for biotechnology and pharmaceutical clients. ...
Isogenica and Cube Biotech Unite to Accelerate GPCR Therapeutics
Isogenica, a global leader in synthetic VHH antibody discovery, has announced a strategic collaboration with Cube Biotech, experts in stabilised protein technologies, to tackle one of the most complex challenges in drug discovery: G protein-coupled receptors (GPCRs). ...
From Hit to Clinic: Isogenica and Charles River Collaborate to Accelerate Next-Generation Peptide and VHH Discovery
Every breakthrough begins with discovery. Isogenica, a leader in synthetic VHH antibody and peptide discovery, has announced a collaboration with Charles River, a leading, global provider of drug discovery, development, and manufacturing solutions, to help biotech companies streamline d...
Cerberus Therapeutics Enters into Antibody Discovery Agreement with Isogenica to Advance Immune-Modulating Therapies
Isogenica Ltd., The VHH Company™, today announced an antibody discovery agreement with Cerberus Therapeutics to support the development of targeted immune-modulating therapies using single-domain antibodies. This agreement brings together Cerberus’s KappaLink™ platform — designed to en...
AI in antibody discovery: Why better data still matters
AI and machine learning are becoming increasingly important in antibody discovery, but the field is moving beyond the idea that computational tools will simply replace experimental science. The most valuable progress is happening where AI is integrated with high-throughput screening, st...
Crossing the blood–brain barrier: Why VHHs matter for CNS Biologics
The blood–brain barrier (BBB) remains one of the hardest challenges in biologics development. Designed to protect the central nervous system, it tightly controls which molecules can enter the brain — but this same selectivity prevents many promising therapeutic formats, including antibo...
Beyond liver uptake: How VHHs could support more targeted LNP delivery
Lipid nanoparticles have become one of the most important delivery platforms for next-generation therapeutics, particularly for payloads such as mRNA, siRNA and oligonucleotides. But many programmes still face a major challenge: how to move beyond liver-dominant uptake and achieve more ...